Blueprint Medicines Corporation shows Risk Adjusted Performance of 0.1 and Mean Deviation of 1.88. Blueprint Medicines technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm future prices. In plain English you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum or the prices will eventually revert. We found nineteen technical drivers for Blueprint Medicines Corporation which can be compared to its rivals. Please confirm Blueprint MedicinesTreynor Ratio as well as the relationship between Potential Upside and Expected Short fall to decide if Blueprint Medicines is priced correctly providing market reflects its regular price of 62.29 per share. Given that Blueprint Medicines has Jensen Alpha of 0.39, we suggest you validate Blueprint Medicines Corporation prevailing market performance to make sure the company can sustain itself at future point.
The output start index for this execution was six with a total number of output elements of eleven. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of Blueprint Medicines volatility. High ATR values indicate high volatility, and low values indicate low volatility. View also all equity analysis or get more info about average true range volatility indicators indicator.
Blueprint Medicines Trend Analysis
Use this graph to draw trend lines for Blueprint Medicines Corporation. You can use it to identify possible trend reversals for Blueprint Medicines as well as other signals and approximate when it will take place. Remember, you need at least two touches of the trend line with actual Blueprint Medicines price movement. To start drawing, click on the pencil icon on top-right. To remove the trend, use eraser icon.
Blueprint Medicines Best Fit Change Line
The following chart estimates an ordinary least squares regression model for Blueprint Medicines Corporation applied against its price change over selected period. The best fit line has a slop of 0.11 % which means Blueprint Medicines Corporation will continue generating value for investors. It has 34 observation points and a regression sum of squares at 10.69, which is the sum of squared deviations for the predicted Blueprint Medicines price change compared to its average price change.
Did you try this?
Run Headlines Timeline Now
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity